Upon injection with AAV-FSTL1, the NAFLD pathway was activated relative to that in AAV-GFP-injected F4MKO mice (Fig. 5a, b). This evidence concerns the gene FSTL1 and metabolic dysfunction-associated steatotic liver disease.